## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.29 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($452.78)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 4, Bearish: 1)

**1. Morgan Stanley downgrades HCA Healthcare stock on peak valuation concerns**
- Source: Investing.com India | 20251215T090207 | Bearish | Relevance: 100%
- Morgan Stanley downgraded HCA Healthcare Inc (NYSE:HCA) from Equalweight to Underweight, setting a price target of $425.00 due to significant stock outperformance and peak valuation multiples. Despite the company's strong execution and shareholder-friendly capital allocation, including substantial share buybacks, the firm warns of potential deceleration in HCA's stock as tailwinds from healthcare policies are expected to ease. HCA's stock has risen 62% year-to-date in 2025, but trades at a high P/E ratio of 18.7 relative to its near-term earnings growth potential.

**2. Hound Partners LLC Sells 3,535 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251214T122523 | Bullish | Relevance: 100%
- Hound Partners LLC has reduced its stake in HCA Healthcare by 10%, selling 3,535 shares and retaining 31,832 shares valued at approximately $12.2 million. Despite this, institutional ownership of HCA remains high at 62.7%, with several other large institutions increasing their positions. HCA has also reported strong quarterly earnings, raised FY2025 guidance, and maintains a "Moderate Buy" consensus rating from analysts.

**3. Public Sector Pension Investment Board Sells 11,216 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251214T105533 | Somewhat-Bullish | Relevance: 100%
- The Public Sector Pension Investment Board reduced its holdings in HCA Healthcare, Inc. by 6.5% during the second quarter, selling 11,216 shares. Despite this, other institutional investors like Norges Bank, Price T Rowe Associates Inc. MD, and Viking Global Investors LP significantly increased their stakes in the company. HCA Healthcare recently posted strong earnings, beating analyst consensus, and declared a quarterly dividend of $0.72 per share.

**4. HCA Healthcare Hits A High But Morgan Stanley Turns Cautious**
- Source: Finimize | 20251215T160841 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has downgraded HCA Healthcare to 'underweight', causing a 2% drop in its share price. The downgrade comes after years of HCA outperforming the market, with analysts citing stretched valuations and the fading impact of post-pandemic patient surges and ACA enrollments as key reasons. This signals a potential shift in sentiment for the healthcare sector as a whole, which may face increased scrutiny.

**5. HCA Downgraded by Morgan Stanley with Price Target Maintained |**
- Source: GuruFocus | 20251215T135017 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has downgraded HCA Healthcare (HCA) from 'Equal-Weight' to 'Underweight', although the price target of $425.00 USD was maintained. This decision follows various analyst ratings, with other firms maintaining 'Buy' or 'Outperform' ratings and increasing price targets for HCA. Despite the downgrade, the average analyst target price is $479.92, suggesting a minor downside, while GuruFocus estimates a 9.69% downside based on its GF Value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.29 suggests fair value with growth premium. Forward P/E 16.0x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.6B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.29 |
| Forward P/E | 16.0 |
| Current P/E | 17.2 |
| YoY Growth | 7.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at -2.2% (minimal 5-day change). Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.0%) - potential reversal signal. Underperforming sector by 3.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.21x) but short-term weakness (below SMA20). MACD histogram bearish (-3.93), momentum weakening. RSI neutral at 48. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.23% (CS: 19) | Weak |
| RSI_14 | 48.0 | Neutral |
| MACD Histogram | -3.93 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.214x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $476.98
- **Stop Loss:** $452.78 (5.1% risk)
- **Target:** $525.38 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $23,372.02
- **Portfolio %:** 23.37%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*